An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

Trial Profile

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Everolimus (Primary) ; Octreotide
  • Indications Pancreatic cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms RADIANT-1
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2010 Results from this study and the other two RADIANT trials will form the basis for regulatory filings in late 2010 according to a Novartis media release.
    • 24 Jun 2009 Final results presented at the 11th World Congress on Gastrointestinal Cancer.
    • 17 Sep 2008 Added Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top